Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Is Catalyst Pharmaceuticals (CPRX) Still Undervalued After its Recent Multi-Year Share Price Surge? [Yahoo! Finance]
Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX) [Yahoo! Finance]
Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? [Yahoo! Finance]